middle.news
How Did Aroa Biosurgery Beat FY25 Revenue Targets and Achieve Positive EBITDA?
8:40am on Thursday 29th of May, 2025 AEST
•
Healthcare
Read Story
How Did Aroa Biosurgery Beat FY25 Revenue Targets and Achieve Positive EBITDA?
8:40am on Thursday 29th of May, 2025 AEST
Key Points
FY25 revenue of NZ$84.7 million beats guidance
Positive normalised EBITDA of NZ$4.2 million achieved
Strong sales growth across Endoform, Myriad, and Symphony products
Cash balance of NZ$22.0 million with positive H2 operating cash flow
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aroa Biosurgery (ASX:ARX)
OPEN ARTICLE